Finally, infiltrated effector CD8+ T cells deprived of continued help through anti-MHC class II antibody treatment failed to maintain optimal effector functions specifically in the pancreas, which, together with reduced effector T cell infiltration, hampered diabetes progression. Here, CD8A is linked to diabetes mellitus.